# Open-label Study of Safety, Tolerability and Pharmacokinetics of Multiple Doses of BI-CON-02 in Patients With HER2-positive Metastatic Breast Cancer, Previously Treated With Trastuzumab

> **NCT03062007** · PHASE1 · TERMINATED · sponsor: **Biointegrator LLC** · enrollment: 6 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** BI-CON-02

## Key facts

- **NCT ID:** NCT03062007
- **Lead sponsor:** Biointegrator LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-09
- **Primary completion:** 2017-06-05
- **Final completion:** 2017-06-05
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Sponsor's decision
- **Last updated:** 2019-07-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03062007

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03062007, "Open-label Study of Safety, Tolerability and Pharmacokinetics of Multiple Doses of BI-CON-02 in Patients With HER2-positive Metastatic Breast Cancer, Previously Treated With Trastuzumab". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03062007. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*